Strategic HTA and Market Access in the Pharmaceutical Industry

The pharmaceutical ecosystem is undergoing a profound paradigm shift where regulatory approval is no longer a guarantee of commercial success. The ultimate arbiters of patient access are now Health Technology Assessment (HTA) bodies and national payers. This comprehensive two-day program bridges the chasm between clinical science and commercial reality, equipping professionals with the frameworks and negotiation tactics required to navigate global payer requirements and secure optimal reimbursement. Participants move from the foundations of HTA and market access strategy, through strategic evidence generation and health economic value demonstration, into pricing dynamics, innovative access agreements, and the global archetypes shaping future policy. The course blends applied frameworks with real payer scenarios so attendees leave able to build a defensible value story and translate it into access and reimbursement outcomes.